The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
Korean Journal of Urological Oncology
; : 30-39, 2021.
Article
em Ko
| WPRIM
| ID: wpr-875302
Biblioteca responsável:
WPRO
ABSTRACT
Urothelial cancer is the seventh most common cancer among men worldwide. Bacille de Calmette-Guérin is a type of anticancer immunotherapy that has been used to treat targeted bladder cancer, but the number of patients with treatment-refractory advanced urothelial cancer, patients has been increasing recently. To overcome this, enfortumab vedotin (novel nectin-4 targeting antibody-drug conjugate) known as antibody-drug conjugate (ADC), was approved. We describe the clinical development process of ADC and the potential for future development as a bladder cancer treatment.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Ko
Revista:
Korean Journal of Urological Oncology
Ano de publicação:
2021
Tipo de documento:
Article